Abstract: Interaction between insulin-like growth factor 1 (IGFI) and integrin is involved in integrin-mediated cellular signaling, such as enhanced proliferation of cells expressing integrins, especially integrin alpha v beta 3, alpha 6 beta. 1 and alpha 6. beta. 4. A method for inhibiting integrin signaling by using an inhibitor of IGFI-integrin binding is disclosed A method for identifying inhibitors of IGFI-integrin binding is also described. Further disclosed are polypeptides, nucleic acids, and corresponding compositions for inhibiting integrin signaling.

Abstract: Interaction between insulin-like growth factor 1 (IGFI) and integrin is involved in integrin-mediated cellular signaling, such as enhanced proliferation of cells expressing integrins, especially integrin alpha v beta 3, alpha 6 beta. 1 and alpha 6. beta. 4. A method for inhibiting integrin signaling by using an inhibitor of IGFI-integrin binding is disclosed A method for identifying inhibitors of IGFI-integrin binding is also described. Further disclosed are polypeptides, nucleic acids, and corresponding compositions for inhibiting integrin signaling.

Abstract: The present invention relates to the discovery that a secretory phospholipase A2 (sPLA2-IIA) plays an active role in mediating inflammatory signaling by way of its specific binding with integrin, especially integrin ?v?3 or ?4?1. More specifically, the invention provides a method for identifying inhibitors of inflammatory signaling by screening for compounds that interrupt the specific binding of sPLA2 and integrin. The invention also provides the novel use of a substance that suppresses the specific binding between sPLA2 and integrin for treating or preventing an inflammatory condition.